Previous Close | 118.03 |
Open | 118.82 |
Bid | 0.00 x 1300 |
Ask | 0.00 x 1100 |
Day's Range | 117.89 - 118.27 |
52 Week Range | 99.13 - 120.01 |
Volume | 18,406 |
Avg. Volume | 156,745 |
Market Cap | 4.577B |
Beta (5Y Monthly) | 0.42 |
PE Ratio (TTM) | 30.89 |
EPS (TTM) | 3.82 |
Earnings Date | May 18, 2021 - May 24, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 102.78 |
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020.
In this article, we discussed Chinese billionaire Zhang Lei’s investment philosophy and his 10 best Hong Kong stocks to buy for 2021. Click to skip ahead and see 5 Best Hong Kong Stocks To Buy for 2021. Hillhouse Capital Group founder and Chinese billionaire Zhang Lei has generated strong returns over the years amid his […]
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that, at an extraordinary general meeting (the "EGM") held today, the Company's shareholders voted in favor of the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of November 19, 2020 (the "Merger Agreement"), among the Company, CBPO Holdings Limited ("Parent") and CBPO Group Limited ("Merger Sub"), pursuant to which, Merger Sub will be merged with and into the Company with the Company continuing as the surviving company and becoming a wholly owned subsidiary of Parent (the "Merger"), the plan of merger (the "Plan of Merger") required to be filed with the Registrar of Companies of the Cayman Islands, and the transactions contemplated thereby, including the Merger.